Fc Domain Amino Acid Substitutions for Glycoform Consistency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The biopharmaceutical industry faces challenges in achieving consistent and reproducible glyco-form profiles for therapeutic antibodies produced in mammalian cell culture systems, leading to variability in product quality and efficacy due to incomplete glycosylation processing and lot-to-lot differences.
Innovation Solution
Introducing specific amino acid substitutions in the Fc domain of antibodies, such as at positions 239, 241, 262, 264, 265, 296, or 301, to enhance glycosylation maturation and minimize culture process-dependent effects, resulting in higher percentages of mature N-linked glycosylation and reduced immature forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional mammalian cell culture systems are used to produce therapeutic antibodies, then the antibodies can be produced, but the glycoform profiles show significant heterogeneity and lot-to-lot variability due to incomplete glycosylation processing
Solution Approach 1:
The patent applies parameter changes by modifying specific amino acid residues in the Fc domain (positions 239, 241, 262, 264, 265, 296, or 301) to alter the protein's interaction with glycosylation enzymes. These residue substitutions change the glycosylation processing parameters to achieve more consistent and complete glycan maturation, reducing heterogeneity and improving batch-to-batch reliability of the antibody product.
2Manufacturing precision
If glucose feeding is controlled to minimize high mannose formation, then glycosylation quality improves, but cell metabolizing rates, growth and productivity decrease
Solution Approach 1:
The patent extracts the glycosylation control function from the external glucose feeding parameters and relocates it to the Fc domain amino acid residues. By modifying these residues, the cell's intrinsic glycosylation processing is enhanced without requiring external metabolic control adjustments, thereby maintaining high cell productivity while achieving superior glycosylation maturation.
3Manufacturing precision
If Fc domain amino acid substitutions are introduced to improve glycosylation maturation, then mature glycan profiles increase, but the protein sequence deviates from wild-type
Solution Approach 1:
The patent applies local quality by making targeted modifications only at specific Fc domain residues (239, 241, 262, 264, 265, 296, or 301) that are known to influence glycosylation, while leaving the rest of the antibody sequence unchanged. This localized approach improves glycosylation consistency without fundamentally altering the overall protein structure or function.
Data Source
AI summary
The present invention relates to variant Fc-containing molecules, such as antibodies and Fc-fusion molecules, having glycosylation characteristics favorable to large-scale production of therapeutic molecules containing such variant Fc.